Siegfried Holding Ltd (SFZN) - Total Assets

Latest as of June 2025: CHF1.97 Billion CHF ≈ $2.49 Billion USD

Based on the latest financial reports, Siegfried Holding Ltd (SFZN) holds total assets worth CHF1.97 Billion CHF (≈ $2.49 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SFZN capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.

Siegfried Holding Ltd - Total Assets Trend (2002–2024)

This chart illustrates how Siegfried Holding Ltd's total assets have evolved over time, based on quarterly financial data. Explore SFZN long-term investments to assets to see how much of total assets are deployed in long-term investments.

Siegfried Holding Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Siegfried Holding Ltd's total assets of CHF1.97 Billion consist of 48.6% current assets and 51.4% non-current assets.

Asset Category Amount (CHF) % of Total Assets
Cash & Equivalents CHF38.76 Million 2.0%
Accounts Receivable CHF411.39 Million 21.3%
Inventory CHF387.58 Million 20.0%
Property, Plant & Equipment CHF909.99 Million 47.1%
Intangible Assets CHF55.89 Million 2.9%
Goodwill CHF0.00 0.0%

Asset Composition Trend (2002–2024)

This chart illustrates how Siegfried Holding Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Siegfried Holding Ltd (SFZN) total market value.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Siegfried Holding Ltd's current assets represent 48.6% of total assets in 2024, an increase from 37.5% in 2002.
  • Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 5.4% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2002.
  • Asset Diversification: The largest asset category is property, plant & equipment at 47.1% of total assets.

Siegfried Holding Ltd Competitors by Total Assets

Key competitors of Siegfried Holding Ltd based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Sweden Skr81.26 Billion
Aurobindo Pharma Limited
NSE:AUROPHARMA
India Rs585.02 Billion
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥14.18 Billion
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
China CN¥19.57 Billion
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
China CN¥10.37 Billion
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
China CN¥7.28 Billion
Xeris Pharmaceuticals Inc
NASDAQ:XERS
USA $392.01 Million
Procter & Gamble Health Limited
NSE:PGHL
India Rs8.94 Billion

Siegfried Holding Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.91 2.70 3.56
Quick Ratio 1.45 1.40 1.83
Cash Ratio 0.11 0.18 0.00
Working Capital CHF618.36 Million CHF606.68 Million CHF430.71 Million

Siegfried Holding Ltd - Advanced Valuation Insights

This section examines the relationship between Siegfried Holding Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.83
Latest Market Cap to Assets Ratio 1.91
Asset Growth Rate (YoY) 3.9%
Total Assets CHF1.93 Billion
Market Capitalization $3.70 Billion USD

Valuation Analysis

Above Book Valuation: The market values Siegfried Holding Ltd's assets above their book value (1.91x), reflecting positive investor sentiment about the company's future prospects.

Positive Asset Growth: Siegfried Holding Ltd's assets grew by 3.9% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Siegfried Holding Ltd (2002–2024)

The table below shows the annual total assets of Siegfried Holding Ltd from 2002 to 2024.

Year Total Assets Change
2024-12-31 CHF1.93 Billion
≈ $2.44 Billion
+3.88%
2023-12-31 CHF1.86 Billion
≈ $2.35 Billion
+3.81%
2022-12-31 CHF1.79 Billion
≈ $2.27 Billion
+7.43%
2021-12-31 CHF1.67 Billion
≈ $2.11 Billion
+34.36%
2020-12-31 CHF1.24 Billion
≈ $1.57 Billion
+6.29%
2019-12-31 CHF1.17 Billion
≈ $1.48 Billion
+5.95%
2018-12-31 CHF1.10 Billion
≈ $1.39 Billion
+3.00%
2017-12-31 CHF1.07 Billion
≈ $1.35 Billion
+4.86%
2016-12-31 CHF1.02 Billion
≈ $1.29 Billion
+1.74%
2015-12-31 CHF1.00 Billion
≈ $1.27 Billion
+59.46%
2014-12-31 CHF629.57 Million
≈ $795.95 Million
+17.07%
2013-12-31 CHF537.77 Million
≈ $679.89 Million
+12.66%
2012-12-31 CHF477.36 Million
≈ $603.51 Million
+6.55%
2011-12-31 CHF448.00 Million
≈ $566.39 Million
-3.46%
2010-12-31 CHF464.05 Million
≈ $586.69 Million
-2.73%
2009-12-31 CHF477.07 Million
≈ $603.14 Million
-10.80%
2008-12-31 CHF534.81 Million
≈ $676.14 Million
-18.81%
2007-12-31 CHF658.74 Million
≈ $832.82 Million
-4.97%
2006-12-31 CHF693.20 Million
≈ $876.39 Million
+2.31%
2005-12-31 CHF677.52 Million
≈ $856.57 Million
+15.65%
2004-12-31 CHF585.82 Million
≈ $740.64 Million
-9.16%
2003-12-31 CHF644.88 Million
≈ $815.30 Million
+9.18%
2002-12-31 CHF590.67 Million
≈ $746.77 Million
--

About Siegfried Holding Ltd

SW:SFZN Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$3.70 Billion
CHF2.93 Billion CHF
Market Cap Rank
#4410 Global
#67 in Switzerland
Share Price
CHF66.90
Change (1 day)
-7.60%
52-Week Range
CHF66.90 - CHF100.00
All Time High
CHF1182.00
About

Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. The company offers drug substances, including exclusive synthesis that manufactures custom APIs. It also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pa… Read more